MedTrace Logo

Dydrogesterone-Primed Ovarian Stimulation Protocol Versus Gonadotropin Releasing Hormone Antagonist Protocol in ICSI

NCT05751681 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2023-03-02

No results posted yet for this study

Summary

GnRH antagonist protocol is currently a good strategy for controlled ovarian stimulation in women with PCOS undergoing IVF/ICSI cycles. Finding a protocol that can be a better alternative will help in improving the success rate of IVF/ICSI cycles

Conditions

  • Ovary Cyst
  • Fertility Issues

Interventions

OTHER

progestin primed ovarian stimulation protocol

progestin primed ovarian stimulation protocol

DRUG

dydrogesterone (Duphaston, Abbott)

20 mg oral dose of dydrogesterone (Duphaston, Abbott)

DRUG

Cetrotide

0.25 mg of Cetrotide (gonadotropin releasing hormone (GnRH) antagonist)

Sponsors & Collaborators

  • Zagazig University

    lead OTHER_GOV

Principal Investigators

  • mostafa fahmy, mcs · zagazig

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-20
Primary Completion
2024-04-20
Completion
2025-03-20

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05751681 on ClinicalTrials.gov